For patients with recurrent ovarian cancer, trebananib did not improve overall survival
the ONA take:
Amgen has announced secondary endpoint results from its TRINOVA-1 study that investigated trebananib plus paclitaxel for the treatment of patients with recurrent ovarian cancer.
The combination therapy did not show a statistically significant improvement in overall survival compared with placebo plus paclitaxel. The TRIANOVA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated trebananib in combination with weekly paclitaxel in women with epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Researchers randomly assigned patients to receiver either trebananib 15mg/kg intravenously weekly plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles or placebo plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles.
Amgen previously announced positive primary endpoint results that showed a statistically significant improvement in progression-free survival in the trebananib group, but secondary endpoint results showed a median overall survival of 19.3 months among those who received trebananib and 18.3 months among those who received placebo.
Despite the disappointing results, trebananib is also being studied in other combinations for the same three cancers. Trebananib is an investigational peptibody that ultimately inhibits angiogenesis, thereby causing cancer cell death.
Results from TRINOVA-1 study that investigated trebananib plus paclitaxel for ovarian cancer.
Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer.
The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|